3 days popular7 days popular1 month popular3 months popular

Novel ‘smart’ insulin automatically adjusts blood sugar in diabetic mouse: Drugs designed to target NHE9 could help to successfully fight glioblastoma

1. For patients with (T1D), the burden of constantly monitoring their and judging when and how much insulin to self-inject, is bad enough. Even worse, a miscalculation or lapse in regimen can cause levels to rise too high (hyperglycemia), potentially leading to heart disease, blindness and other long-term complications, or to plummet too low (hypoglycemia), which in the worst cases can result in coma or even death.

'Smart' Insulin Automatically Adjusts Blood Sugar Levels
At time 0 mice with a diabetes-like condition were given a long-acting insulin that is currently prescribed to diabetics (blue), or Ins-PBA-F “smart” insulin (red) and compared to healthy mice that were not injected with insulin (black). At 3 hours, the mice were given a dose of sugar. Blood sugar returns to normal as quickly in treated with Ins-PBA-F “smart” insulin as in healthy mice.
Credit:Danny Chou


Other authors of the report include Kalyan Kondapalli, Jose Llongueras, Vivian Capilla-Gonzalez, Hari Prasad, Anniesha Hack, Christopher Smith and Hugo Guerrero-Cazares of the Johns Hopkins University School of Medicine.

This work was supported by grants from the National Institute of Neurological Disorders and Stroke (NS070024), the National Institute of Diabetes and Digestive and Kidney Diseases (DK054214), the National Institute of General Medical Sciences (GM62142), the (11POST7380034), the , the International Fulbright Science and Technology Award, and the American Physiological Society’s Porter Physiology Development Fellowship.

NIH/National Institute of Neurological Disorders and Stroke, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association, Johns Hopkins Post-Baccalaureate Research Education Program, International Fulbright Science and Technology.

University of Utah Health Sciences